Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2018 | Research

Paired box 8 suppresses tumor angiogenesis and metastasis in gastric cancer through repression of FOXM1 via induction of microRNA-612

Authors: Liyan Wang, Xiaotong Bo, Qinghua Zheng, Wenhong Ge, Yanhua Liu, Bin Li

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2018

Abstract

Background

Paired box 8 (PAX8) has been documented to be downregulated in gastric cancer. However, its biological function in this malignancy is poorly understood.

Methods

In the present work, we investigated the effects of PAX8 overexpression and knockdown on the aggressive phenotype of gastric cancer cells. We further checked the involvement of forkhead box M1 (FOXM1), a ubiquitously expressed oncogene that can facilitate gastric cancer progression, in the action of PAX8.

Results

Ectopic expression of PAX8 blocked the migration and invasion of both AGS and SGC-7901 cells, but had no effect on cell proliferation. Conversely, knockdown of PAX8 enhanced gastric cancer cell migration and invasion. PAX8 overexpression inhibited epithelial-mesenchymal transition (EMT) and pro-angiogenic activity of gastric cancer cells. Mechanistically, PAX8 overexpression downregulated FOXM1 by stimulating microRNA (miR)-612 expression. Ectopic expression of miR-612 recapitulated the effect of PAX8 overexpression on gastric cancer cells, causing an inhibition of migration, invasion, EMT, and angiogenesis. Knockdown of miR-612 or overexpression of FOXM1 significantly reversed the tumor-suppressive activity of PAX8. In vivo studies further demonstrated that PAX8 overexpression restrained tumor angiogenesis and metastasis in nude mice, which was accompanied by increased expression of miR-612 and decreased expression of FOXM1.

Conclusions

PAX8 exerts a tumor-suppressive effect against gastric cancer cells, largely through induction of miR-612 and repression of FOXM1. Therefore, restoration of PAX8 expression may offer therapeutic benefits in the treatment of gastric cancer.

Relaix F. Pax genes: master regulators of development and tissue homeostasis. Semin Cell Dev Biol. 2015;44:62–3.CrossRefPubMed

Apuzzo S, Gros P. Cooperative interactions between the two DNA binding domains of Pax3: helix 2 of the paired domain is in the proximity of the amino terminus of the homeodomain. Biochem. 2007;46:2984–93.CrossRef

Liu Q, Yang G, Qian Y. Loss of MicroRNA-489-3p promotes osteosarcoma metastasis by activating PAX3-MET pathway. Mol Carcinog. 2017;56:1312–21.CrossRefPubMed

Martin-Montalvo A, Lorenzo PI, López-Noriega L, Gauthier BR. Targeting pancreatic expressed PAX genes for the treatment of diabetes mellitus and pancreatic neuroendocrine tumors. Expert Opin Ther Targets. 2017;21:77–89.CrossRefPubMed

Zhang J, Qin X, Sun Q, Guo H, Wu X, Xie F, et al. Transcriptional control of PAX4-regulated miR-144/451 modulates metastasis by suppressing ADAMs expression. Oncogene. 2015;34:3283–95.CrossRefPubMed

Chang HY, Ye SP, Pan SL, Kuo TT, Liu BC, Chen YL, et al. Overexpression of miR-194 reverses HMGA2-driven signatures in colorectal Cancer. Theranostics. 2017;7:3889–900.CrossRefPubMedPubMedCentral

Rosignolo F, Sponziello M, Durante C, Puppin C, Mio C, Baldan F, et al. Expression of PAX8 target genes in papillary thyroid carcinoma. PLoS One. 2016;11:e0156658.CrossRefPubMedPubMedCentral

López-Urrutia E, Pedroza-Torres A, Fernández-Retana J, De Leon DC, Morales-González F, Jacobo-Herrera N, et al. PAX8 is transcribed aberrantly in cervical tumors and derived cell lines due to complex gene rearrangements. Int J Oncol. 2016;49:371–80.CrossRefPubMed

Khanlou N, Shintaku P, Yi J, Moatamed NA. Evaluation of PAX8 expression in brain tissue and related neoplasms. Appl Immunohistochem Mol Morphol. 2016;24:207–9.CrossRefPubMed

10.

Mhawech-Fauceglia P, Wang D, Samrao D, Godoy H, Pejovic T, Liu S, et al. Pair-box (PAX8) protein-positive expression is associated with poor disease outcome in women with endometrial cancer. Br J Cancer. 2012;107:370–4.CrossRefPubMedPubMedCentral

11.

Di Palma T, Lucci V, de Cristofaro T, Filippone MG, Zannini M. A role for PAX8 in the tumorigenic phenotype of ovarian cancer cells. BMC Cancer. 2014;14:292.CrossRefPubMedPubMedCentral

12.

Stiekema A, Van de Vijver KK, Boot H, Broeks A, Korse CM, van Driel WJ, et al. Human epididymis protein 4 immunostaining of malignant ascites differentiates cancer of Müllerian origin from gastrointestinal cancer. Cancer. 2017;125:197–204.

13.

Zhang X, Lv QL, Huang YT, Zhang LH, Zhou HH. Akt/FoxM1 signaling pathway-mediated upregulation of MYBL2 promotes progression of human glioma. J Exp Clin Cancer Res. 2017;36:105.CrossRefPubMedPubMedCentral

14.

Hou XW, Sun X, Yu Y, Zhao HM, Yang ZJ, Wang X, et al. miR-361-5p suppresses lung cancer cell lines progression by targeting FOXM1. Neoplasma. 2017;64:526–34.CrossRefPubMed

15.

Yang L, Cui M, Zhang L, Song L. FOXM1 facilitates gastric cancer cell migration and invasion by inducing Cathepsin D. Oncotarget. 2017;8:68180–90.PubMedPubMedCentral

16.

Feng J, Wang X, Zhu W, Chen S, Feng C. MicroRNA-630 suppresses epithelial-to-mesenchymal transition by regulating FoxM1 in gastric Cancer cells. Biochemistry (Mosc). 2017;82:707–14.CrossRef

17.

Li X, Liang J, Liu YX, Wang Y, Yang XH. Bao-Hongluan et al. knockdown of the FoxM1 enhances the sensitivity of gastric cancer cells to cisplatin by targeting Mcl-1. Pharmazie. 2016;71:345–8.PubMed

18.

Duan W, Gao L, Wu X, Wang L, Nana-Sinkam SP, Otterson GA, et al. MicroRNA-34a is an important component of PRIMA-1-induced apoptotic network in human lung cancer cells. Int J Cancer. 2010;127:313–20.PubMedPubMedCentral

19.

Pietras A, von Stedingk K, Lindgren D, Påhlman S, Axelson H. JAG2 induction in hypoxic tumor cells alters notch signaling and enhances endothelial cell tube formation. Mol Cancer Res. 2011;9:626–36.CrossRefPubMed

20.

Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993;143:401–9.PubMedPubMedCentral

21.

Mi L, Zhu F, Yang X, Lu J, Zheng Y, Zhao Q, et al. The metastatic suppressor NDRG1 inhibits EMT, migration and invasion through interaction and promotion of caveolin-1 ubiquitylation in human colorectal cancer cells. Oncogene. 2017;36:4323–35.CrossRefPubMedPubMedCentral

22.

Zhang L, Zhang W, Li Y, Alvarez A, Li Z, Wang Y, et al. SHP-2-upregulated ZEB1 is important for PDGFRα-driven glioma epithelial-mesenchymal transition and invasion in mice and humans. Oncogene. 2016;35:5641–52.CrossRefPubMedPubMedCentral

23.

Dupain C, Ali HM, Mouhoub TA, Urbinati G, Massaad-Massade L. Induction of TTF-1 or PAX-8 expression on proliferation and tumorigenicity in thyroid carcinomas. Int J Oncol. 2016;49:1248–58.CrossRefPubMed

24.

Ye J, Huang J, Xu J, Huang Q, Wang J, Zhong W, et al. ERp29 controls invasion and metastasis of gastric carcinoma by inhibition of epithelial-mesenchymal transition via PI3K/Aktsignaling pathway. BMC Cancer. 2017;17:626.CrossRefPubMedPubMedCentral

25.

Myatt SS, Lam EW. The emerging roles of forkhead box (fox) proteins in cancer. Nat Rev Cancer. 2007;7:847–59.CrossRefPubMed

26.

Miao L, Xiong X, Lin Y, Cheng Y, Lu J, Zhang J, Cheng N. Down-regulation of FoxM1 leads to the inhibition of the epithelial-mesenchymal transition in gastric cancer cells. Cancer Genet. 2014;207:75–82.CrossRefPubMed

27.

Tao ZH, Wan JL, Zeng LY, Xie L, Sun HC, Qin LX, et al. miR-612 suppresses the invasive-metastatic cascade in hepatocellular carcinoma. J Exp Med. 2013;210:789–803.CrossRefPubMedPubMedCentral

28.

Sheng L, He P, Yang X, Zhou M, Feng Q. miR-612 negatively regulates colorectal cancer growth and metastasis by targeting AKT2. Cell Death Dis. 2015;6:e1808.CrossRefPubMedPubMedCentral

Title: Paired box 8 suppresses tumor angiogenesis and metastasis in gastric cancer through repression of FOXM1 via induction of microRNA-612
Authors: Liyan Wang
Xiaotong Bo
Qinghua Zheng
Wenhong Ge
Yanhua Liu
Bin Li
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2018
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-018-0830-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

SP1-induced lncRNA AGAP2-AS1 expression promotes chemoresistance of breast cancer by epigenetic regulation of MyD88

PHD-finger domain protein 5A functions as a novel oncoprotein in lung adenocarcinoma

TSSC3 promotes autophagy via inactivating the Src-mediated PI3K/Akt/mTOR pathway to suppress tumorigenesis and metastasis in osteosarcoma, and predicts a favorable prognosis

Recent advances in searching c-Myc transcriptional cofactors during tumorigenesis

Classification of triple-negative breast cancers based on Immunogenomic profiling

Novel role of miR-133a-3p in repressing gastric cancer growth and metastasis via blocking autophagy-mediated glutaminolysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer